** Shares of drugmaker PTC Therapeutics PTCT.O fall 1% to $54.38
** PTCT says the European Commission has decided not to renew marketing authorization for the company's muscle-wasting disorder drug, Translarna, and that the treatment will no longer be available for sale in the EU
** The drug had received conditional approval in EU in 2014 to treat children aged five years and older who can walk and are afflicted with Duchenne muscular dystrophy
** Company says it plans to work with countries individually to maintain commercial availability of the drug where possible
** TD Cowen analyst Joseph Thome estimates Translarna to generate $192 million in sales for 2025, with a "minimal contribution from the EU"
** Shares have gained 86.8% in the last 12 months, as of last close
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.